However, the ligant PD-L1 is often overexpressed in different tumor including lymphoma, melanoma, non-small-cell lung cancer and other types, making the PD-1/PD-L1 signaling pathway crucial in dampening the immune surveillance of the tumor29. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.